Daré Bioscience, Inc. (NASDAQ:DARE) Sees Large Decline in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 35,400 shares, a decrease of 9.7% from the August 31st total of 39,200 shares. Based on an average trading volume of 46,900 shares, the short-interest ratio is presently 0.8 days. Currently, 0.4% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC raised its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. Institutional investors own 6.70% of the company’s stock.

Daré Bioscience Trading Up 0.5 %

Shares of NASDAQ DARE traded up $0.02 during midday trading on Friday, hitting $3.27. 10,490 shares of the company’s stock were exchanged, compared to its average volume of 46,369. The business’s fifty day moving average price is $3.44 and its two-hundred day moving average price is $4.29. The company has a market cap of $27.54 million, a price-to-earnings ratio of -0.85 and a beta of 1.39. Daré Bioscience has a 12-month low of $3.05 and a 12-month high of $7.56.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating the consensus estimate of ($0.57) by $2.09. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.60 million. Equities analysts expect that Daré Bioscience will post -0.27 earnings per share for the current fiscal year.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.